Previous 10 | Next 10 |
CAMBRIDGE, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today that it has raised gross proceeds of approximately $28.9 mi...
CAMBRIDGE, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today it has entered into a clinical trial collaboration with Me...
CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced five scientific posters sharing updated preclinical data a...
CAMBRIDGE, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that data from the Phase 1 study of SRF231, a fully human,...
CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that its chief executive officer, Jeff Goater, will present at the ...
Surface Oncology (NASDAQ: SURF ): Q1 GAAP EPS of $0.74 beats by $0.54 . More news on: Surface Oncology, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the first qu...
Thinly traded nano cap Surface Oncology ( SURF +4.6% ) is up on below-average volume on the heels of its announcement that it has initiated a Phase 1 clinical trial evaluating escalating doses of interleukin-27 (IL-27) inhibitor SRF388 in patients with advanced solid tumors. More news ...
CAMBRIDGE, Mass., April 23, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has initiated a Phase 1 clinical trial of i...
Stating the obvious, Baird analysts have created three lists of healthcare companies that may be worth a look considering their attractive valuations or relatively strong capitalizations amid the COVID-19 selloff. More news on: IDEAYA Biosciences, Inc., Surface Oncology, Inc., Jounce Thera...
News, Short Squeeze, Breakout and More Instantly...
Surface Oncology Inc. Company Name:
SURF Stock Symbol:
NASDAQ Market:
Surface Oncology Inc. Website:
San Diego-based cannabis company Gelato Canna Co. announced the launch of its newest products, Geebs gummy edibles and pre rolls, in honor of pr...
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Surface Oncology Inc. (SURF) is expected to report $-0.36 for Q3 2023